Brickell Biotech

$1.31
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.11 (+9.09%) Today
-$0.01 (-0.76%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell BBI and other stocks, options, and ETFs commission-free!

About BBI

Brickell Biotech, Inc. engages in the development of prescription therapeutics for the treatment of skin diseases. Its pipeline consists of new molecular entities targeting the treatment of the following indications: hyperhidrosis, allergic contact dermatitis, androgenic alopecia, cutaneous t-cell lymphoma and psoriasis. The company was founded by Reginald L. Hardy and Andrew D. Sklawer in 2009 and is headquartered in Boulder, CO. The listed name for BBI is Brickell Biotech, Inc. Common Stock.

CEO
Robert B. Brown
Employees
15
Headquarters
Boulder, Colorado
Founded
2009
Market Cap
71.66M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
6.26M
High Today
$1.37
Low Today
$1.24
Open Price
$1.24
Volume
2.10M
52 Week High
$3.44
52 Week Low
$0.466

BBI Earnings

-$2.44
-$1.63
-$0.81
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 17, After Hours

You May Also Like

MAAC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure